A Multi-center, 2-Phase, Double-blind, Randomized, Placebo-controlled, Parallel Trial to Evaluate the Efficacy of a Single Dose of Zolmitriptan (Zomig) as Acute Treatment in Phase I and Repeated Doses as Preemptive Treatment in Phase II for Menstrual Migraine Headache.
Study identifier:311CUS/0003
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Multi-center, 2-Phase, Double-blind, Randomized, Placebo-controlled, Parallel Trial to Evaluate the Efficacy of a Single Dose of Zolmitriptan (Zomig) as Acute Treatment in Phase I and Repeated Doses as Preemptive Treatment in Phase II for Menstrual Migraine Headache.
Medical condition
migraine
Phase
Phase 3
Healthy volunteers
-
Study drug
-
Sex
-
Actual Enrollment
-
Study type
Interventional
Age
-
Date
Study Start Date: 01 Aug 2000
Primary Completion Date: -
Study Completion Date: -
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Nov 2013 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
